Terms: = Leukemia AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
392 results:
1. Regulation of cytokine and chemokine expression by histone lysine methyltransferase MLL1 in rheumatoid arthritis synovial fibroblasts.
Okamoto K; Araki Y; Aizaki Y; Tanaka S; Kadono Y; Mimura T
Sci Rep; 2024 May; 14(1):10610. PubMed ID: 38719857
[TBL] [Abstract] [Full Text] [Related]
2. Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.
Stefańczyk SA; Hagelstein I; Lutz MS; Müller S; Holzmayer SJ; Jarjour G; Zekri L; Heitmann JS; Salih HR; Märklin M
Blood Cancer J; 2024 Apr; 14(1):67. PubMed ID: 38637557
[TBL] [Abstract] [Full Text] [Related]
3. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract] [Full Text] [Related]
4. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
5. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia.
Zhang K; Huang R; Ji M; Lin S; Lai F; Wu D; Tian H; Bi J; Peng S; Hu J; Sheng L; Li Y; Chen X; Xu H
Eur J Med Chem; 2024 Jan; 264():116015. PubMed ID: 38048697
[TBL] [Abstract] [Full Text] [Related]
6. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
[TBL] [Abstract] [Full Text] [Related]
7. The iron chelator and OXPHOS inhibitor VLX600 induces mitophagy and an autophagy-dependent type of cell death in glioblastoma cells.
Reisbeck L; Linder B; Tascher G; Bozkurt S; Weber KJ; Herold-Mende C; van Wijk SJL; Marschalek R; Schaefer L; Münch C; Kögel D
Am J Physiol Cell Physiol; 2023 Dec; 325(6):C1451-C1469. PubMed ID: 37899749
[TBL] [Abstract] [Full Text] [Related]
8. Dietary γ-mangostin triggers immunogenic cell death and activates cGAS signaling in acute myeloid leukemia.
Long ZJ; Wang JD; Qiu SX; Zhang Y; Wu SJ; Lei XX; Huang ZW; Chen JJ; Yang YL; Zhang XZ; Liu Q
Pharmacol Res; 2023 Nov; 197():106973. PubMed ID: 37898441
[TBL] [Abstract] [Full Text] [Related]
9. Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement.
Gray ZH; Chakraborty D; Duttweiler RR; Alekbaeva GD; Murphy SE; Chetal K; Ji F; Ferman BI; Honer MA; Wang Z; Myers C; Sun R; Kaniskan HÜ; Toma MM; Bondarenko EA; Santoro JN; Miranda C; Dillingham ME; Tang R; Gozani O; Jin J; Skorski T; Duy C; Lee H; Sadreyev RI; Whetstine JR
Cell; 2023 Oct; 186(21):4528-4545.e18. PubMed ID: 37788669
[TBL] [Abstract] [Full Text] [Related]
10. The emerging role of DOT1L in cell proliferation and differentiation: Friend or foe.
Wu D; Zhang J; Jun Y; Liu L; Huang C; Wang W; Yang C; Xiang Z; Wu J; Huang Y; Meng D; Yang Z; Zhou X; Cheng C; Yang J
Histol Histopathol; 2024 Apr; 39(4):425-435. PubMed ID: 37706592
[TBL] [Abstract] [Full Text] [Related]
11. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A; Singh S; Xu-Monette ZY; Coyle KM; Hilton LK; Chavdoula E; Ranganathan P; Jain N; Hanel W; Tsichlis P; Alinari L; Peterson BR; Tao J; Muthusamy N; Baiocchi R; Epperla N; Young KH; Morin R; Sehgal L
Leukemia; 2023 Oct; 37(10):2094-2106. PubMed ID: 37598282
[TBL] [Abstract] [Full Text] [Related]
12. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
[TBL] [Abstract] [Full Text] [Related]
13. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract] [Full Text] [Related]
14. ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to fgfr1 inhibitors through amino acid metabolic reprogramming.
Zhang ZJ; Wu QF; Ren AQ; Chen Q; Shi JZ; Li JP; Liu XY; Zhang ZJ; Tang YZ; Zhao Y; Yao NN; Zhang XY; Liu CP; Dong G; Zhao JX; Xu MJ; Yue YQ; Hu J; Sun F; Liu Y; Ao QL; Zhou FL; Wu H; Zhang TC; Zhu HC
Acta Pharmacol Sin; 2023 Nov; 44(11):2282-2295. PubMed ID: 37280363
[TBL] [Abstract] [Full Text] [Related]
15. Interplay between PML NBs and HIRA for H3.3 dynamics following type I interferon stimulus.
Kleijwegt C; Bressac F; Seurre C; Bouchereau W; Cohen C; Texier P; Simonet T; Schaeffer L; Lomonte P; Corpet A
Elife; 2023 May; 12():. PubMed ID: 37227756
[TBL] [Abstract] [Full Text] [Related]
16. Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-fgfr1 rearrangement.
Dhangar S; Shanmukhaiah C; Sawant L; Ghatanatti J; Shah A; Mathan S LP; Vundinti BR
Cancer Genet; 2023 Jun; 274-275():26-29. PubMed ID: 36965231
[TBL] [Abstract] [Full Text] [Related]
17. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
[TBL] [Abstract] [Full Text] [Related]
18. Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review.
Sharma R; Suravarjhula L; Banerjee M; Kumar G; Kumar N
Curr Drug Res Rev; 2023; 15(3):241-261. PubMed ID: 36825696
[TBL] [Abstract] [Full Text] [Related]
19. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
Nat Commun; 2023 Feb; 14(1):809. PubMed ID: 36781850
[TBL] [Abstract] [Full Text] [Related]
20. Myeloid/lymphoid neoplasm with eosinophilia and BCR/fgfr1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report.
Isaza AP; Quintero SC; González LPQ; Córdoba FEA; Olivar AFA; Ocaña JCB
J Med Case Rep; 2023 Jan; 17(1):39. PubMed ID: 36698221
[TBL] [Abstract] [Full Text] [Related]
[Next]
